Gilpin Wealth Management’s Cytokinetics CYTK Stock Holding History

Gilpin Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$132	Buy	+2	New	+$153	﹤0.01%	1246

Other funds holding CYTK

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return

Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return

Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return

Gilpin Wealth Management's CYTK Position: Q3 2026 in Review

Gilpin Wealth Management opened a new position in Cytokinetics (CYTK) in Q3 2026: 2 shares worth $132. The stake represents ﹤0.01% of the portfolio and ranks #1246 among its holdings.

10 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

Gilpin Wealth Management held 2 shares of Cytokinetics worth $132 as of Q3 2026.
Cytokinetics was a new Gilpin Wealth Management position in Q3 2026.
Cytokinetics made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1246 holding.
10 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.